GlassScriptPhysician profile
John S Boswell
NPI 1295936961
$777,376.22
in general payments reported to CMS, 2019-2025
43 companies · $178K in 2025
The $178K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $49K · 2021: $49K · 2022: $128K · 2023: $165K · 2024: $161K · 2025: $178K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $424K · Consulting Fee: $28K · Travel and Lodging: $21K · Food and Beverage: $18K · Honoraria: $14K · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $423,699.33 |
| Consulting Fee | $27,748.00 |
| Travel and Lodging | $20,591.38 |
| Food and Beverage | $17,708.31 |
| Honoraria | $13,600.00 |
| Education | $211.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $204,876.09 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $104,803.86 | 2019-2025 | |
| Janssen Biotech, INC. | $75,925.52 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $75,437.08 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $58,082.00 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $53,156.36 | 2020-2023 | Tremfya |
| Galderma Laboratories, L.P. | $44,933.17 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Pfizer INC. | $42,037.78 | 2019-2025 | |
| Leo Pharma INC. | $32,619.17 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $27,723.84 | 2019-2025 | |
| Ucb, INC. | $22,437.11 | 2019-2025 | Bimzelx, Cimzia |
| Organon LLC | $15,566.54 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,347.73 | 2022-2025 | Spevigo |
| Incyte Corporation | $951.64 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $800.53 | 2022-2025 | Sotyktu |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $734.91 | 2019-2025 | Winlevi, Ilumya |
| Amgen INC. | $665.23 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $531.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $474.96 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.67 | 2020-2024 | Jublia, Arazlo, Cabtreo |
| Helsinn Therapeutics (U.S.), INC. | $104.75 | 2019-2024 | Valchlor |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Revance Therapeutics, INC. | $85.58 | 2024-2025 | Daxxify |
| Strata Skin Sciences, INC. | $85.30 | 2024-2025 | Xtrac |
| Verrica Pharmaceuticals INC. | $84.51 | 2024 | Ycanth |
| Almirall LLC | $82.16 | 2019-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $65.64 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $62.33 | 2019-2020 | |
| Botanix Sb INC | $58.38 | 2025 | Sofdra |
| Allergan, INC. | $54.46 | 2019-2022 | |
| Epi Health, LLC | $46.49 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $39.91 | 2025 | Acthar |
| Promius Pharma LLC | $39.52 | 2019 | |
| Sandoz INC. | $36.90 | 2019 | |
| Biofrontera INC. | $36.20 | 2024-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Prugen, INC. Pharmaceuticals | $28.60 | 2019 | |
| Lnhc, INC | $24.70 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $23.66 | 2022 | |
| Dusa Pharmaceuticals, INC. | $22.91 | 2019 | |
| Celgene Corporation | $22.27 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $21.10 | 2019 | |
| Genentech USA, INC. | $18.40 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.